Novo Nordisk diversifies with $2.1bn deal to buy Corvidia

Novo Nordisk has taken another step towards expanding beyond its heartlands of diabetes and obesity with a deal to buy US biotech Corvidia Therapeutics and its lead drug for ch

Coronavirus to disrupt EU pharma drug launches, analysts war...

Big European launches of drugs for cancer, HIV, and sickle cell disease could be affected by coronavirus, according to a new analysis from Jefferies.

Could GLP-1 drugs treat space headaches? NASA wants to know.

Experts from NASA are keeping a close eye on UK research that tests whether drugs commonly used in diabetes work against raised brain pressure – a painful problem sometimes seen in women wi

FDA approves MACE label claim for Lilly’s Trulicity

Ozempic acceleration buoys Novo Nordisk, and threatens Lilly

Novo Nordisk nears EU okay for oral GLP-1 drug Rybelsus afte...

The EMA's main advisory committee has backed approval of Novo Nordisk's oral GLP-1 agonist Rybelsus, a key pipeline drug in its type 2 diabetes franchise.